Results 71 to 80 of about 310,786 (327)

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells. [PDF]

, 2019
Tumor cells harboring stem-like/cancer stem cell (CSC) properties have been identified and isolated from numerous hematological and solid malignancies.
Ames, Erik, Bouzid, Lyes A, Canter, Robert J, Darrow, Morgan A, Grossenbacher, Steven K, Judge, Sean J, Luna, Jesus I, Murphy, William J, Sturgill, Ian R   +8 more
core   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Novel Immunotherapeutic Approach in Gastric Cancer

Acta Medica Bulgarica, 2020
Gastric cancer (GC) is suitable for immunotherapy because 80% of it display microsatellite and chromosomal instability, some mutations and DNA hypermethylation. Therefore, GC is more immunogenic.
Gulubova M., Hadzhi M., Ignatova M., Chonov D., Balakan O., Aydan M., Ananiev J.   +6 more
doaj   +1 more source

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]

, 2015
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni, Biron, Björklund, Brodin, Bryceson, Burns, Campbell, Cooley, Cooper, Cooper, Curti, Davies, Di Santo, Di Santo, Farag, Fehniger, Fogler, Foley, Freud, Gasser, Gilfillan, Grimm, Guethlein, Herberman, Huntington, Joncker, Kiessling, Killig, King, Kröger, Lajoie, Lanier, Leong, Ljunggren, Lowe, Lundqvist, Mancusi, McQueen, Miller, Moretta, Moretta, Moretta, Nguyen, Oevermann, Ouyang, Perussia, Phillips, Romagnani, Romee, Rosenberg, Rosenberg, Rosenberg, Ruggeri, Santoni, Stabile, Stabile, Stern, Stringaris, Thielens, Torelli, Trinchieri, Trinchieri, Vago, Valés-Gómez, Venstrom, Vivier, Whitelaw, Zorn   +67 more
core   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Journal for ImmunoTherapy of Cancer, 2017
Chimeric antigen receptor (CAR) T-cell therapy represents a revolutionary treatment for haematological malignancies (i.e. B-ALL). However, the success of this type of treatment has not yet been achieved in solid tumors.
Irene Scarfò, Marcela V. Maus
doaj   +1 more source

Long-term survival after immunotherapy and targeted therapy without chemotherapy in an elderly patient with HER2-positive gastroesophageal junction cancer: A case report

Human Vaccines & Immunotherapeutics, 2022
A 74-yr-old man underwent thoracic laparoscopy combined with radical gastrectomy, and the postoperative pathological diagnosis was esophageal and gastric cardia cancer pT3N1M0, pStage IIB. Immunohistochemical staining for HER2 (3+) and PD-L1 (
Wei-Ling Li, Ying Zhang, Xiao-Ling Zhang, Yun-Yi Du, Wen-Qing Hu, Jun Zhao   +5 more
doaj   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Adoptive transfer of tumor specific T cells from allogeneic donors is feasible, effective and safe alternative to autologous T cell based tumor immunotherapy

Journal of Medical Science, 2014
Donor lymphocyte infusion is used to increase the graft versus tumor (GVT) effect after allogeneic hematopoietic cell transplant. The limited spectrum of activity and high risk of graft versus host disease (GVHD) remain major limitations of this approach.
Eliza P. Kwiatkowska-Borowczyk, Anna Kozłowska, Klaudia Maruszak, Luiza Kańczuga-Koda, Mariusz Koda, Monika Dajnowiec, Andrzej Mackiewicz, Dariusz W. Kowalczyk   +7 more
doaj   +1 more source